Proportion of extended-spectrum β-lactamase (ESBL)-producing isolates among enterobacteriaceae in Africa: Evaluation of the evidence-systematic review

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 5, 2014, Pages 1177-1184

  Tansarli, Giannoula S ^a   Poulikakos, Panagiotis ^a,b   Kapaskelis, Anastasios ^a,b   Falagas, Matthew E ^a,c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b MITERA HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Citrobacter; E. coli; Enterobacter; Escherichia coli; K. pneumoniae; Klebsiella; Morganella; Percentage; Proteus; Providencia; Resistance; Salmonella; Serratia; Shigella

Indexed keywords

CEFTRIAXONE; CEPHALOSPORIN; BETA LACTAMASE;

AFRICA; ARTICLE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; DATA BASE; EGYPT; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HUMAN; INTENSIVE CARE UNIT; MALAWI; MEDLINE; SYSTEMATIC REVIEW; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; EPIDEMIOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PREVALENCE; SECRETION (PROCESS);

AFRICA; BETA-LACTAMASES; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; PREVALENCE;

EID: 84898464318     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt500     Document Type: Article

References (46)

1. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBLproducing Enterobacteriaceae in Europe. Euro Surveill 2008; 13: pii1/419044.
2. Fennell J, Vellinga A, Hanahoe B et al. Increasing prevalence of ESBL production among Irish clinical Enterobacteriaceae from 2004 to 2008: an observational study. BMC Infect Dis 2012; 12: 116.
3. Muro S, Garza-Gonzalez E, Camacho-Ortiz A et al. Risk factors associated with extended-spectrum b-lactamase-producing Enterobacteriaceae nosocomial bloodstream infections in a tertiary care hospital: a clinical and molecular analysis. Chemotherapy 2012; 58: 217-24.
4. Park SY, Kang CI, Joo EJ et al. Risk factors for multidrug resistance in nosocomial bacteremia caused by extended-spectrum b-lactamaseproducing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist 2012; 18: 518-24.
5. Sankar S, Narayanan H, Kuppanan S et al. Frequency of extendedspectrum b-lactamase (ESBL)-producing Gram-negative bacilli in a 200-bed multi-specialty hospital in Vellore district, Tamil Nadu, India. Infection 2012; 40: 425-9.
6. Kim B, Kim J, Seo MR et al. Clinical characteristics of communityacquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea. Infection 2013; 41: 603-12.
7. Sood S, Gupta R. Antibiotic resistance pattern of community acquired uropathogens at a tertiary care hospital in Jaipur, Rajasthan. Indian J Community Med 2012; 37: 39-44.
8. Kang CI, Kim SH, Kim DM et al. Risk factors for ciprofloxacin resistance in bloodstream infections due to extended-spectrum b-lactamaseproducing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist 2004; 10: 71-6.
9. Yu WL, Jones RN, Hollis RJ et al. Molecular epidemiology of extendedspectrum b-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan. J Clin Microbiol 2002; 40: 4666-9.
10. Vardakas KZ, Tansarli GS, Rafailidis PI et al. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum b-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012; 67: 2793-803.
11. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum b-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60: 913-20.
12. Ahoyo AT, Baba-Moussa L, Anago AE et al. [Incidence of infections due to Escherichia coli strains producing extended spectrum b-lactamase, in the Zou/Collines Hospital Centre (CHDZ/C) in Benin]. Med Mal Infect 2007; 37: 746-52.
13. Aibinu I, Odugbemi T, Koenig Wet al. Sequence type ST131 and ST10 complex (ST617) predominant among CTX-M-15-producing Escherichia coli isolates from Nigeria. Clin Microbiol Infect 2012; 18: E49-51.
14. Bamford C, Bonorchis K, Ryan A et al. Antimicrobial susceptibility patterns of Escherichia coli strains isolated from urine samples in South Africa from 2007-2011. South Afr J Epidemiol Infect 2012; 27: 46-52.
15. Barguigua A, El Otmani F, Talmi M et al. Characterization of extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates from the community in Morocco. J Med Microbiol 2011; 60: 1344-52.
16. Barguigua A, El Otmani F, Talmi M et al. Prevalence and genotypic analysis of plasmid-mediated b-lactamases among urinary Klebsiella pneumoniae isolates in Moroccan community. J Antibiot (Tokyo) 2013; 66: 11-6.
17. Ben Haj Khalifa A, Khedher M. [Epidemiological study of Klebsiella spp. uropathogenic strains producing extended-spectrum b-lactamase in a Tunisian university hospital, 2009]. Pathol Biol (Paris) 2012; 60: e1-5.
18. Bercion R, Mossoro-Kpinde D, Manirakiza A et al. Increasing prevalence of antimicrobial resistance among Enterobacteriaceae uropathogens in Bangui, Central African Republic. J Infect Dev Ctries 2009; 3: 187-90.
19. Blomberg B, Jureen R, Manji KP et al. High rate of fatal cases of pediatric septicemia caused by gram-negative bacteria with extended-spectrum b-lactamases in Dar es Salaam, Tanzania. J Clin Microbiol 2005; 43: 745-9.
20. Bouzenoune F, Boudersa F, Bensaad A et al. [Urinary tract infections in Ain M'lila (Algeria). Antibiotic resistance of 239 strains isolated between 2006 and 2007]. Med Mal Infect 2009; 39: 142-3.
21. Brink A, Moolman J, da Silva MCet al. Antimicrobial susceptibility profile of selected bacteraemic pathogens from private institutions in South Africa. S Afr Med J 2007; 97: 273-9.
22. Brink AJ, Botha RF, Poswa X et al. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART study 2004-2009): impact of the new carbapenem breakpoints. Surg Infect (Larchmt) 2012; 13: 43-9.
23. Dromigny JA, Nabeth P, Juergens-Behr A et al. Risk factors for antibiotic-resistant Escherichia coli isolated from community-acquired urinary tract infections in Dakar, Senegal. J Antimicrob Chemother 2005; 56: 236-9.
24. Fam N, Leflon-Guibout V, Fouad S et al. CTX-M-15-producing Escherichia coli clinical isolates in Cairo (Egypt), including isolates of clonal complex ST10 and clones ST131, ST73, and ST405 in both community and hospital settings. Microb Drug Resist 2011; 17: 67-73.
25. Frank T, Arlet G, Gautier V et al. Extended-spectrum b-lactamaseproducing Enterobacteriaceae, Central African Republic. Emerg Infect Dis 2006; 12: 863-5.
26. Gray KJ, Wilson LK, Phiri A et al. Identification and characterization of ceftriaxone resistance and extended-spectrum b-lactamases in Malawian bacteraemic Enterobacteriaceae. J Antimicrob Chemother 2006; 57: 661-5.
27. Habte TM, Dube S, Ismail N et al. Hospital and community isolates of uropathogens at a tertiary hospital in South Africa. S Afr Med J 2009; 99: 584-7.
28. Iabadene H, Messai Y, Ammari H et al. Prevalence of plasmid-mediated AmpC b-lactamases among Enterobacteriaceae in Algiers hospitals. Int J Antimicrob Agents 2009; 34: 340-2.
29. Keddy KH, Sooka A, Crowther-Gibson P et al. Systemic shigellosis in South Africa. Clin Infect Dis 2012; 54: 1448-54.
30. Kohli R, Omuse G, Revathi G. Antibacterial susceptibility patterns of blood stream isolates in patients investigated at the Aga Khan University Hospital, Nairobi. East Afr Med J 2010; 87: 74-80.
31. Muvunyi CM, Masaisa F, Bayingana C et al. Decreased susceptibility to commonly used antimicrobial agents in bacterial pathogens isolated from urinary tract infections in Rwanda: need for new antimicrobial guidelines. Am J Trop Med Hyg 2011; 84: 923-8.
32. Nedjai S, Barguigua A, Djahmi N et al. Prevalence and characterization of extended spectrum b-lactamases in Klebsiella-Enterobacter-Serratia group bacteria, in Algeria. Med Mal Infect 2012; 42: 20-9.
33. Ogbolu DO, Daini OA, Ogunledun A et al. High levels of multidrug resistance in clinical isolates of Gram-negative pathogens from Nigeria. Int J Antimicrob Agents 2011; 37: 62-6.
34. Olowe OA, Grobbel M, Buchter B et al. Detection of blaCTX-M-15 extended-spectrum b-lactamase genes in Escherichia coli from hospital patients in Nigeria. Int J Antimicrob Agents 2010; 35: 206-7.
35. Saied T, Elkholy A, Hafez SF et al. Antimicrobial resistance in pathogens causing nosocomial bloodstream infections in university hospitals in Egypt. Am J Infect Control 2011; 39: e61-5.
36. Sire JM, Nabeth P, Perrier-Gros-Claude JD et al. Antimicrobial resistance in outpatient Escherichia coli urinary isolates in Dakar, Senegal. J Infect Dev Ctries 2007; 1: 263-8.
37. Zohoun A, Ngoh E, Bajjou Tet al. [Epidemiological features of multidrug resistant bacteria isolated from urine samples at the Mohammed V Military Teaching Hospital in Rabat, Morocco]. Med Trop (Mars) 2010; 70: 412-3.
38. Tansarli GS, Athanasiou S, Falagas ME. Evaluation of antimicrobial susceptibility of Enterobacteriaceae causing urinary tract infections in Africa. Antimicrob Agents Chemother 2013; 57: 3628-39.
39. Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum b-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother 2012; 67: 1311-20.
40. Bochicchio GV, Baquero F, Hsueh PR et al. In vitro susceptibilities of Escherichia coli isolated from patients with intra-abdominal infections worldwide in 2002-2004: results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Surg Infect (Larchmt) 2006; 7: 537-45.
41. European Centre for Disease Prevention and Control. Antimicrobial Resistance Surveillance in Europe, Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2011. http:// www.ecdc.europa.eu/en/publications/publications/antimicrobial-resistancesurveillance-europe-2011.pdf (31 May 2013, date last accessed).
42. Balode A, Punda-Polic V, Dowzicky MJ. Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2004-2010. Int J Antimicrob Agents 2013; 41: 527-35.
43. Turner PJ. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis 2008; 60: 185-92.
44. Becker J, Drucker E, Enyong P et al. Availability of injectable antibiotics in a town market in southwest Cameroon. Lancet Infect Dis 2002; 2: 325-6.
45. Okeke IN, Sosa A. Antibiotic Resistance in Africa-Discerning the Enemy and Plotting a Defense. http://www.tufts.edu/med/apua/about_issue/ africahealth.pdf (7 June 2013, date last accessed).
46. Tansarli GS, Karageorgopoulos DE, Kapaskelis A et al. Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Rev Anti Infect Ther 2013; 11: 321-31.